Virtual, Remote, and Decentralized Part 2: Better Clinical Care Driving Transformative Change in 2021

Published Date: Jan 01, 2021

COVID-19 ushered in a new era of clinical research, the biggest advantages of which are just beginning to surface. In 2021, the life sciences industry will see more remote trial designs adopted by a larger and broader group of sponsors, sites, and patients.

Author(s)

Jena Daniels

Jena Daniels

Director, Research & Academics

Medable

Mr. Rasmus Hogreffe

Mr. Rasmus Hogreffe

Decentralized Clinical Trials Expert, Vice President of DCT Innovation

Medable

Ms. Alison Holland

Ms. Alison Holland

Head of Decentralized Trials

Medable

Alison (Ali) Holland is Head of Decentralized and Remote trials at Medable and is chartered to design and expand the end-to-end capabilities needed to partially or fully virtualize clinical studies, building on the commitment to reduce clinical trial times by 50%. Ali has over 20 years of experience in a variety of leadership roles, including Feasibility Head and Six Sigma Black Belt at Covance, and Business Head and global General Manager at Roche/Genentech in one of their therapeutic area business groups. Having been engaged in over 300 studies across biotechs, pharma and all geographies, Ali brings an incomparable level of insight and technical excellence on the matter of operational needs for sites and patients.

Dr. Michelle Longmire

Dr. Michelle Longmire

Co-Founder and Chief Executive Officer

Medable Inc.

Michelle Longmire MD, is Co-founder and Chief Executive Officer of Medable. Dr. Longmire is a Stanford-trained physician-entrepreneur dedicated to transforming healthcare through innovation. Dr. Longmire has a background in epigenetics, novel diagnostics, and imaging. Dr. Longmire founded Medable in 2014 to enable healthcare technology to be as seamless, integrated, and adaptive as the human body.

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.